FDA Clears IND Application for CER-1236 in Advanced Solid Tumors
Source: Targeted Oncology, April 2025
A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.
- The FDA has cleared a second investigational new drug (IND) application for CER-1236 in advanced solid tumors.
- CER-1236 is a novel chimeric antigen receptor (CAR) T-cell therapy.
- A phase 1 trial will evaluate the agent as a potential treatment for patients with advanced solid tumors, including non–small cell lung cancer (NSCLC) and ovarian cancer.
The FDA has granted clearance for a second IND application for CER-1236 in advanced solid tumors, specifically NSCLC and ovarian cancer.1 A second phase 1 clinical trial of the agent will be initiated.